The present invention provides an ophthalmic composition in which (a) a geranyl geranyl acetone (GGA) and (b) a retinal disease therapeutic agent (but excluding GGA) are coexisted, thereby suppressing a side effect of conjunctival injection and/or corneal problem resulted from (b) the retinal disease therapeutic agent (but excluding GGA). In addition, the present ophthalmic composition suppresses white turbidity of the ophthalmic composition and the adsorption of GGA on a container, and improves thermal stubility and/or photo stability.本發明之眼科用製劑,係藉由使(a)香葉基香葉基丙酮(GGA)及(b)視網膜病變治療藥劑(但,係GGA以外者)共存,以抑制(b)視網膜病變治療藥劑(但,係GGA以外者)所致的結膜充血及/或角膜損傷之副作用。同時,抑制眼科用組成物之白濁、及GGA吸附在容器上。而且,提高GGA對熱及/或光之安定性。本案圖式皆為實驗數據,不足以代表本案。
